"use strict";(self.webpackChunkBenStockTracker=self.webpackChunkBenStockTracker||[]).push([[1745],{1745:e=>{e.exports=JSON.parse('{"114da786-5ff7-3101-b079-e58cdef3c07a":{"uuid":"114da786-5ff7-3101-b079-e58cdef3c07a","title":"Health Canada Approves AbbVie\'s RINVOQ\xae (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis","publisher":"CNW Group","link":"https://finance.yahoo.com/news/health-canada-approves-abbvies-rinvoq-194500452.html","providerPublishTime":1658346300,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/nRH7ZIM.6lWE2xi20lPM_Q--~B/aD00MDA7dz0xNDM7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/nUYvt.qu8Xq3rp0P0nTxtw--~B/aD00MDA7dz0xNDM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/b3d97f583457433958bcb3361bd41467","width":143,"height":400,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/SDESQ_.6MOgtD8pigSSdVw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/nUYvt.qu8Xq3rp0P0nTxtw--~B/aD00MDA7dz0xNDM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/b3d97f583457433958bcb3361bd41467","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["ABBV"]},"49ae05c8-43b6-3211-8f39-36f935a47d94":{"uuid":"49ae05c8-43b6-3211-8f39-36f935a47d94","title":"AbbVie, iSTAR Medical Inks Strategic Alliance For Glaucoma Treatment","publisher":"Benzinga","link":"https://finance.yahoo.com/news/abbvie-istar-medical-inks-strategic-152940601.html","providerPublishTime":1658330980,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/Y7tls2VWo2xZKvtjUWCDUQ--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/Ona4d8EB_vY8G98khq0EAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/90216b3c5f020d842587d9d0be4c26f6","width":600,"height":400,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/46W8Y84maqAnxKpMB7GP7Q--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/Ona4d8EB_vY8G98khq0EAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/90216b3c5f020d842587d9d0be4c26f6","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["ABBV"]},"61b820c8-2d95-3a63-9889-54631d5aa97d":{"uuid":"61b820c8-2d95-3a63-9889-54631d5aa97d","title":"Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance","publisher":"Zacks","link":"https://finance.yahoo.com/news/biogen-biib-beats-q2-earnings-131401344.html","providerPublishTime":1658322841,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/TkIXrbWZvU.aXJ724Cls.Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","width":635,"height":400,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/fX7MWTL9XJfxixwF.RKfjA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["BIIB","ABBV"]},"171f74d8-2c7c-38cf-940a-fcc840b00371":{"uuid":"171f74d8-2c7c-38cf-940a-fcc840b00371","title":"AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma","publisher":"PR Newswire","link":"https://finance.yahoo.com/news/abbvie-istar-medical-announce-strategic-110000587.html","providerPublishTime":1658314800,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/E4AEBZrdmI.hazTgmZXGTw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/uOcMFW6WP9L7B9cdwe_Rig--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/51a7a6f663d0152535408e965077ec6f","width":16,"height":16,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/GGNh88IzKd.R8t3lFN8dMQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/uOcMFW6WP9L7B9cdwe_Rig--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/51a7a6f663d0152535408e965077ec6f","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["ABBV"]},"cc87734f-bbb6-368e-a99b-0c68fd301ce6":{"uuid":"cc87734f-bbb6-368e-a99b-0c68fd301ce6","title":"J&J (JNJ) Beats on Q2 Earnings & Sales, Lowers 2022 Guidance","publisher":"Zacks","link":"https://finance.yahoo.com/news/j-j-jnj-beats-q2-132501120.html","providerPublishTime":1658237101,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/6hgtO7luBTc3xSFU5hzSIg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/UjHemYIeF2aWxwD7gqDihg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761","width":635,"height":400,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/4K8GabCkmtDgO.0ZkJi.oQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/UjHemYIeF2aWxwD7gqDihg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["JNJ","ABBV"]},"61afe8d5-0043-3c2f-a795-f0a530194b09":{"uuid":"61afe8d5-0043-3c2f-a795-f0a530194b09","title":"3 Dividend Growth Stocks You Can Buy Now and Hold Forever","publisher":"Motley Fool","link":"https://finance.yahoo.com/m/61afe8d5-0043-3c2f-a795-f0a530194b09/3-dividend-growth-stocks-you.html","providerPublishTime":1658221980,"type":"STORY","relatedTickers":["ABT","ABBV","JNJ"]},"ee46ae4e-605c-3332-8521-53f6e971e60c":{"uuid":"ee46ae4e-605c-3332-8521-53f6e971e60c","title":"AbbVie (ABBV) Seeks EU Nod for Atogepant to Prevent Migraine","publisher":"Zacks","link":"https://finance.yahoo.com/news/abbvie-abbv-seeks-eu-nod-152003745.html","providerPublishTime":1658157603,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/sBy0Jqrq1puvNI83AuaseQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/J5PJq8rtkuiBcDVdnbD5LA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227","width":635,"height":400,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/rFj6uz1yhoLFyrXhNS1E4Q--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/J5PJq8rtkuiBcDVdnbD5LA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["ABBV","BHVN","PFE","MRK"]},"94f7f15d-d7b9-3bd5-bea9-50b8fb665167":{"uuid":"94f7f15d-d7b9-3bd5-bea9-50b8fb665167","title":"AbbVie To Submit European Application For Epcoritamab In Lymphoma Setting Later In 2022","publisher":"Benzinga","link":"https://finance.yahoo.com/news/abbvie-submit-european-application-epcoritamab-150515984.html","providerPublishTime":1658156715,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/YZRdUeIln0c6gb2qtn2niw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/HlgWiNP59PVBUu6r6dwNXA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/5fda512e9023d444ae7f8fde8e71fefb","width":600,"height":400,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/WWMzx8.xUWBpbSupGl8KHg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/HlgWiNP59PVBUu6r6dwNXA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/5fda512e9023d444ae7f8fde8e71fefb","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["ABBV","GMAB.CO"]}}')}}]);